Launxp Biomedical Co (ROCO:6876) Beneish M-Score: 0.00 (As of Jun. 28, 2026)


ROCO:6876 Launxp Biomedical Co Ltd ROCO:6876
11 GF Score
Price NT$15.90
! 4 Warning Signs
View Full Analysis

What is Launxp Biomedical Co Beneish M-Score?

Launxp Biomedical Co ROCO:6876 -0.93% 11 Beneish M-Score is 0.00 as of Jun. 28, 2026. GuruFocus rates ROCO:6876 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 829 Biotechnology companies, Launxp Biomedical Co ranks worse than 120627.14% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Launxp Biomedical Co's Beneish M-Score or its related term are showing as below:

During the past 6 years, the highest Beneish M-Score of Launxp Biomedical Co was 197.31. The lowest was 197.31. And the median was 197.31.

Launxp Biomedical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Launxp Biomedical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Launxp Biomedical Co Beneish M-Score Chart

Launxp Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 0.00 0.00 0.00 197.31 0.00

Launxp Biomedical Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 197.31 0.00 0.00

ROCO:6876 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Launxp Biomedical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Launxp Biomedical Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Launxp Biomedical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Launxp Biomedical Co's Beneish M-Score falls into.


ROCO:6876
11GF Score
Launxp Biomedical Co Ltd ROCO:6876
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Launxp Biomedical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Launxp Biomedical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$0.03 Mil.
Revenue was NT$0.00 Mil.
Gross Profit was NT$0.00 Mil.
Total Current Assets was NT$94.40 Mil.
Total Assets was NT$403.03 Mil.
Property, Plant and Equipment(Net PPE) was NT$8.40 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$2.53 Mil.
Selling, General, & Admin. Expense(SGA) was NT$60.29 Mil.
Total Current Liabilities was NT$138.34 Mil.
Long-Term Debt & Capital Lease Obligation was NT$13.05 Mil.
Net Income was NT$-110.01 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-135.09 Mil.
 Total Receivables was NT$0.00 Mil.
Revenue was NT$2.48 Mil.
Gross Profit was NT$2.29 Mil.
Total Current Assets was NT$104.92 Mil.
Total Assets was NT$123.91 Mil.
Property, Plant and Equipment(Net PPE) was NT$3.52 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$2.40 Mil.
Selling, General, & Admin. Expense(SGA) was NT$46.94 Mil.
Total Current Liabilities was NT$13.93 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1.11 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.034 / 0) / (0 / 2.484)
= / 0
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2.285 / 2.484) / (0 / 0)
=0.919887 /
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (94.398 + 8.398) / 403.034) / (1 - (104.921 + 3.517) / 123.911)
=0.744945 / 0.124872
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0 / 2.484
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(2.401 / (2.401 + 3.517)) / (2.525 / (2.525 + 8.398))
=0.405711 / 0.231164
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(60.286 / 0) / (46.941 / 2.484)
= / 18.897343
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((13.045 + 138.339) / 403.034) / ((1.112 + 13.934) / 123.911)
=0.375611 / 0.121426
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-110.01 - 0 - -135.091) / 403.034
=0.06223

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.00 mean?
Launxp Biomedical Co (ROCO:6876) has a Beneish M-Score of 0.00 as of Jun. 28, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Launxp Biomedical Co and its competitors. Over the past decade, Launxp Biomedical Co's Beneish M-Score has ranged from 197.31 to 197.31. According to the industry distribution chart, Launxp Biomedical Co ranks #999999 out of 829 companies in the Biotechnology industry.
Is Launxp Biomedical Co's Beneish M-Score too high?
Launxp Biomedical Co's current Beneish M-Score is 0.00. Over the past 10 years, this metric has ranged from a low of 197.31 to a high of 197.31. Based on the distribution chart, Launxp Biomedical Co ranks #999999 out of 829 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Launxp Biomedical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Launxp Biomedical Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Launxp Biomedical Co ranks #999999 out of 829 companies for Beneish M-Score. This places Launxp Biomedical Co in the lower half of its industry. Historically, Launxp Biomedical Co's own Beneish M-Score has ranged from 197.31 to 197.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Launxp Biomedical Co and its competitors. Launxp Biomedical Co's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Launxp Biomedical Co stock overvalued right now?
Launxp Biomedical Co (ROCO:6876) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Launxp Biomedical Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Launxp Biomedical Co (ROCO:6876), the current Beneish M-Score is 0.00 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Launxp Biomedical Co Business Description

Address 10F, No. 51, Section 2, Gongyi Road, Nantun District, Taichung, TWN, 408
Launxp Biomedical Co Ltd is a company that researches, designs and develops Cancer drug rapid screening platform and Early development evaluation and technology licensing of generic drugs for cancer treatment. The company mainly focuses on the screening of development drugs, formulation of development strategies, project management, planning and execution of regulations and clinical trials, etc.
11GF Score

Get the complete analysis for ROCO:6876

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.90
Price